Anthonet Koen
Clinical Trials Lead
About
Anthonet Koen joined the Vaccines and Infectious Diseases Analytics (VIDA) Research Unit of the University of the Witwatersrand, as a medical officer in 2008 after completing her community service and undergraduate studies at the University of the Free State and having a special interest in the fields of paediatrics, clinical research and disease prevention.
As part of the clinical team, which she currently leads, Anthonet had been sub-investigator on more than 20 clinical trials ranging from phase I-III, and principal investigator on three. These include trials on pneumococcal, meningococcal, rotavirus, influenza, RSV, group B streptococcus and measles vaccines. She is also the co-author on 14 vaccine-related publications.
Publications
2023. ChAdOx1 nCoV-19 (AZD1222) vaccine-induced Fc receptor binding tracks with differential susceptibility to COVID-19.  Nat Immunol 24(7):1161-1172
,2023. Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages.  Sci Rep 13(1):1222
,2023. Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.  Lancet Infect Dis 23(3):295-306
,2023. T-cell responses induced by ChAdOx1 nCoV-19 (AZD1222) vaccine to wild-type severe acute respiratory syndrome coronavirus 2 among people with and without HIV in South Africa.  AIDS 37(1):105-112
,2023. Efficacy of primary series AZD1222 (ChAdOx1 nCoV-19) vaccination against SARS-CoV-2 variants of concern: Final analysis of a randomized, placebo-controlled, phase 1b/2 study in South African adults (COV005).  Vaccine 41(23):3486-3492
,2023. Longitudinal IgA and IgG Response, and ACE2 Binding Blockade, to Full-Length SARS-CoV-2 Spike Protein Variants in a Population of Black PLWH Vaccinated with ChAdOx1 nCoV-19.  Viruses 15.
,2023. Single priming and booster dose of ten-valent and 13-valent pneumococcal conjugate vaccines and Streptococcus pneumoniae colonisation in children in South Africa: a single-centre, open-label, randomised trial.  Lancet Child Adolesc Health 7(5):326-335
,2023. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults.  N Engl J Med 388(16):1465-1477
,2023. Evaluation of Clinical Case Definitions for Respiratory Syncytial Virus Lower Respiratory Tract Infection in Young Children.  J Pediatric Infect Dis Soc 12(5):273-281
,2022. Safety and immunogenicity of VPM1002 versus BCG in South African newborn babies: a randomised, phase 2 non-inferiority double-blind controlled trial.  Lancet Infect Dis 22(10):1472-1483
,2021. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial.  Lancet HIV 8(9):e568-e580
,2021. Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant.  N Engl J Med 384(20):1899-1909
,2021. Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant.  N Engl J Med 384(20):1885-1898
,2021. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials.  Lancet 397(10277):881-891
,2021. Immunogenicity and safety of a hexavalent pediatric vaccine in HIV-exposed infected and uninfected infants in Republic of South Africa.  Hum Vaccin Immunother 17(6):1770-1778
,2021. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.  Lancet 397(10269):99-111
,2021. Safety and immunogenicity of a plant-derived rotavirus-like particle vaccine in adults, toddlers and infants.  Vaccine 39(39):5513-5523
,2020. Short-term immunogenicity and safety of hepatitis-A and varicella vaccines in HIV-exposed uninfected and HIV-unexposed South African children.  Vaccine 38(22):3862-3868
,2020. Impact of HIV status and vaccination schedule on bacterial nasopharyngeal carriage following infant immunisation with the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in South Africa.  Vaccine 38(10):2350-2360
,2020. Safety and immunogenicity of a parenteral trivalent P2-VP8 subunit rotavirus vaccine: a multisite, randomised, double-blind, placebo-controlled trial.  Lancet Infect Dis 20(7):851-863
,2020. Respiratory Syncytial Virus Vaccination during Pregnancy and Effects in Infants.  N Engl J Med 383(5):426-439
,2020. HLA antibody repertoire in infants suggests selectivity in transplacental crossing.  Am J Reprod Immunol 84(2):e13264
,2020. Bacterial nasopharyngeal carriage following infant immunization with pneumococcal conjugate vaccines according to a 2+1 schedule in children in South Africa: an exploratory analysis of two clinical trials.  Expert Rev Vaccines 19(12):1177-1189
,2020. Immunogenicity of a single-dose compared with a two-dose primary series followed by a booster dose of ten-valent or 13-valent pneumococcal conjugate vaccine in South African children: an open-label, randomised, non-inferiority trial.  Lancet Infect Dis 20(12):1426-1436
,2019. Immunogenicity and Safety of an Early Measles Vaccination Schedule at 6 and 12 Months of Age in Human Immunodeficiency Virus (HIV)-Unexposed and HIV-Exposed, Uninfected South African Children.  J Infect Dis 220(9):1529-1538
,2019. Neutrophil Counts in Healthy South African Infants: Implications for Enrollment and Adverse Event Grading in Clinical Trials in an African Setting.  J Pediatr X 1:100005
,2017. Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial.  Expert Rev Vaccines 16(6):641-656
,2017. Vaccination with 10-valent pneumococcal conjugate vaccine in infants according to HIV status.  Medicine (Baltimore) 96(2):e5881
,2017. Safety and immunogenicity of a parenteral P2-VP8-P[8] subunit rotavirus vaccine in toddlers and infants in South Africa: a randomised, double-blind, placebo-controlled trial.  Lancet Infect Dis 17(8):843-853
,2017. Antibody Kinetics and Response to Routine Vaccinations in Infants Born to Women Who Received an Investigational Trivalent Group B Streptococcus Polysaccharide CRM197-Conjugate Vaccine During Pregnancy.  Clin Infect Dis 65(11):1897-1904
,2016. Safety and immunogenicity of an investigational maternal trivalent group B streptococcus vaccine in healthy women and their infants: a randomised phase 1b/2 trial.  Lancet Infect Dis 16(8):923-34
,2016. Group B streptococcus vaccination in pregnant women with or without HIV in Africa: a non-randomised phase 2, open-label, multicentre trial.  Lancet Infect Dis 16(5):546-555
,2015. Burden of invasive group B Streptococcus disease and early neurological sequelae in South African infants.  PLoS One 10(4):e0123014
,2014. Effect of breastfeeding on immunogenicity of oral live-attenuated human rotavirus vaccine: a randomized trial in HIV-uninfected infants in Soweto, South Africa.  Bull World Health Organ 92(4):238-45
,2013. Immunogenicity of seven-valent pneumococcal conjugate vaccine administered at 6, 14 and 40 weeks of age in South African infants.  PLoS One 8(8):e72794
,2013. Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles/mumps/rubella and varicella vaccines at 15-18 months of age in healthy South African infants.  Pediatr Infect Dis J 32(8):889-97
,2013. Acquisition of Streptococcus pneumoniae in pneumococcal conjugate vaccine-naïve South African children and their mothers.  Pediatr Infect Dis J 32(5):e192-205
,2011. Trivalent inactivated influenza vaccine in African adults infected with human immunodeficient virus: double blind, randomized clinical trial of efficacy, immunogenicity, and safety.  Clin Infect Dis 52(1):128-37
,Publication list retrieved from NCBI using ImpactPubs
.